Rockefeller Capital Management
LRMR icon

Rockefeller Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Rockefeller Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$451 Sell
148
-1,811
-92% -$7.19K ﹤0.01% 4608
2026
Q1 		$8.82K Buy
1,959
+1,811
+1,224% +$7.24K ﹤0.01% 4046
2025
Q4 		$564 Buy
+148
New +$576 ﹤0.01% 4514

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Rockefeller Capital Management's LRMR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Larimar Therapeutics (LRMR) stake by 92% in Q2 2026, selling an estimated $7.19K and leaving 148 shares worth $451. The position accounts for ﹤0.01% of the portfolio, ranked #4608.

Rockefeller Capital Management first reported a position in LRMR in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.82K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Rockefeller Capital Management held 148 shares of Larimar Therapeutics worth $451 as of Q2 2026.
  • Rockefeller Capital Management sold 1,811 Larimar Therapeutics shares in Q2 2026, an estimated $7.19K.
  • Larimar Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4608 holding.
  • Rockefeller Capital Management first reported a position in Larimar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rockefeller Capital Management's Larimar Therapeutics position peaked at $8.82K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.